Programme

Topics

Topic 1 - New Developments in Congenital Muscle Disease
Topic 2 - Neuropathies and Non-5q Motor Neuron Disease
Topic 3 - The Development of Therapeutic Approaches
 

Each day a plenary session will be dedicated to the selected topics. Speakers will summarise the state of the field on the selected topics, covering clinical, molecular and other aspects.

Click here for individual registration

Meet the Speakers

WMS actively discourages any congress sponsor or other organisation from organising any kind of meeting or event in parallel with the congress programme. Any meeting or event which is organised before or after the congress must not be badged in anyway as a pre/post WMS event for example, nor any connection be made to attendees being able to attend as part of their WMS itinerary.

Congress Programme

• The summary and full programme is available to download as a PDF document below.
• The sessions will comprise of invited speakers, selected oral presentations, a debate, poster highlights and late breaking news.
• Delegates will also have the opportunity to attend poster presentations and interact with presenters.

View the Summary Congress Programme

View the Full Congress Programme

Programme Key

I = Invited Speaker
O/LBO = Selected Oral Presentation
P/LBP = Poster Presentation (on display at the venue as a poster and e-poster and on the virtual platform)
VP = Virtual Poster Presentation (on display on the virtual platform and on e-poster boards at the venue)
FP = Selected Flash Poster Presentation (short flash talk in dedicated area + poster presentation as above)
LBP = Late Breaking Poster (on display at the venue as a poster and e-poster and on the virtual platform)
LSVP = Late Submitted Virtual Poster (only on display on the virtual platform and on e-poster boards at the venue)

See https://www.wms2022.com/page/poster-presentations for further information on the different types of poster presentation

Please note, all times stated in the programme are in Local Halifax, Canada (ADT) time.